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Abstract
Background: The presence of IgG antibodies to HPV-16 L1-virus like particles (VLPs) in serum has been reported as
a result of persistent exposure to the virus and as a marker of disease progression. However, detection of VLP-
specific antibodies in sera does not always indicate a malignant lesion as positive results may also be due to a
nonmalignant viral infection. Furthermore, malignant lesions are associated with an increased antibody titer for E6
and E7 proteins. The aim of this study was to develop an ELISA using a novel chimeric virus-like particle (cVLP)
encoding an L1 protein fused with a string of HPV-16 E6 and E7 seroreactive epitopes to its C-terminus to be used
for detection of HPV-16 specific antibodies in patients with cervical intraepithelial lesion grade 1 (CIN 1).
Results: The sera of 30 patients with CIN 1 who also tested positive for HPV-16 DNA and of 30 age-matched
normal donors negative for HPV infection were tested for the presence of IgG antibodies specific for either VLP-L1
(HPV-16 L1), gVLP (derived from Gardasil), or cVLP by ELISA. The cVLP-reactive sera yielded two distinct groups of
results: (H) reactivity levels that presented very strong cVLP-specific titers, and (L) reactivity levels with significantly
lower titers similar to those obtained with VLP-L1 and gVLP antigens. Additionally, the sera that presented the
higher cVLP titers closely matched those that had significantly stronger reactivity to E6 and E7 epitopes.
Interestingly, the samples with the highest titers corresponded to patients with the higher numbers of sexual
partners and pregnancies. On the other hand only 4 out of the 12 sera that harbored antibodies with VLP
neutralizing ability corresponded to the group with high cVLP antibody titers.
Conclusion: We report for the first time that chimeric particles containing HPV-16 L1 protein fused with E6 and E7
seroreactive epitopes enable much better detection of IgG antibodies in the sera of CIN 1 patients positive for
HPV-16 infection than those obtained with VLPs containing only the HPV-16 L1 protein. We also found that the
sera with higher cVLP antibody titers corresponded to patients with more sexual partners and pregnancies, and
not always with to those with a high neutralizing activity. This novel assay could help in the development of a tool
to evaluate cervical cancer risk.
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Infection of the genital epithelium with human papilloma-
virus (HPV) is a common sexually transmitted disease, as
well as a significant public health burden in developing
countries. Most cervicovaginal HPV infections are clini-
cally inapparent and produce no cytological abnormalities.
However, persistent infections with certain high-risk HPV
strains can cause cervical cancer, which is the second
most common cancer in women worldwide and accounts
for 250,000 deaths annually [1]. High-risk HPV strains,
such as HPV-16, HPV-18, and others, are detectable with
sensitive polymerase chain reaction (PCR) methods and
are present in more than 95% of all abnormal cervical
cytology samples [2]. Notably, HPV-16 accounts for 50%
to 60% of all HPV DNA-positive cervical cancers [3]. HPV
DNA encodes a range of early (E) functional and late (L)
structural capsid proteins that are immunogenic. L1 is the
major capsid protein of HPV. The oncogenic E6 and E7
proteins are expressed in tumor tissues at all stages of can-
cer progression and interfere with p53 and the retinoblas-
toma gene product to maintain the proliferative status of
HPV-infected tumor cells [4].
Studies of the immune response to HPV have pro-
gressed slowly, due in part to the lack of suitable
reagents for immunologic assays. During the last two
decades, serologic studies have been important in under-
standing the natural history of HPV infections and
efforts are ongoing to develop reliable genotype-specific
assays. In this context, the observation that HPV capsid
proteins generated in eukaryotic expression systems self-
assemble into virus-like particles (VLPs) has enabled the
use of these particles as reagents for studies of the
immune response to HPV [5-9].
A number of studies have demonstrated that human
sera can react with HPV VLPs and that this reactivity is
largely HPV- and strain-specific [10-12]. In addition, a
strong association between HPV-VLP antibody seroposi-
tivity and the development of cervical lesions or the pro-
gression of these lesions to cervical cancer has been
demonstrated [13-15]. Previous epidemiological studies
have shown that the presence of HPV-16 VLP-specific
antibodies is associated with a 12.5 times increased risk
for subsequent development of either carcinoma in situ
or invasive cervical cancer [16,17]. However, despite
data demonstrating these associations, the presence of
VLP-specific antibodies is not necessarily indicative of
viral infection as antibody detection is strongly asyn-
chronous with infection and the antibody response to
HPV proteins does not invariably occur during a natural
HPV infection. In fact, it has been reported that
humoral immune response to VLPs is induced in about
half of women with normal cytology who have HPV
DNA present in their cervical epithelium [17].
The presence of antibodies specific for the viral tumor
a n t i g e n sE 6a n dE 7i sc o n s i d e r e dt h eb e s tm a r k e rf o r
cervical cancer progression. This is because the magni-
tude of the antibody response is influenced by the stage
of disease and the size of tumor mass [18-20]. Optimal
detection of antibodies specific for L1 in conjunction
with those specific for E6 and E7 antigens may be
important in understanding HPV seroconversion in
patients with primary lesions, as well as to evaluate the
clinical outcome of viral infections and the progression
from infection to cervical cancer.
In the present study, we developed an ELISA to detect
cVLP-specific IgG antibodies in serum samples from
patients with incipient lesions such as cervical intrae-
pithelial lesion grade 1 (CIN 1) that were also positive
for HPV-16 infection. This ELISA utilizes a novel chi-
meric VLP (cVLP) composed of HPV-16 L1 and a string
of E6 and E7 epitopes fused to the C-terminus [21].
Interestingly, the cVLPs used in this study enabled sig-
nificantly improved detection of IgG antibodies in these
patients versus the results obtained using VLPs contain-
ing only the HPV-16 L1 protein.
Results
Detection of IgG antibodies specific for virus-like particles
in serum samples
A total of 230 female patients with CIN 1 were analyzed
for the presence of HPV DNA by PCR, and only the
sera from the 30 patients who tested positive for HPV-
16 infection were included in this study. On the other
hand, serum samples from 30 women without clinical or
molecular evidence of HPV infection were used as nega-
tive control for these experiments. The mean age of the
experimental subjects was of 32.1(16-43) years while in
the normal donors was of 36.4(19-47). The reported
mean of sexual partners and pregnancies of the patients
was of 1.7(1-5) and 2.5(1-5) respectively, while in the
normal donors was of 1.2(1-3) and 1.1(1-3). The sera
and clinical data from all participants were taken after
their informed consent and according to the ethical and
confidentiality requirements concerning work with
human samples of the institutions involved.
The presence of IgG antibodies specific for three types
of VLPs was determined by ELISA. Two of the VLPs
were plant-derived and composed of either the HPV-16
L1 protein (VLP-L1) or a chimeric particle containing
H P V - 1 6L 1a n das t r i n go fE 6a n dE 7k n o w na n t i g e n i c
peptides fused to the C-terminus (cVLP). The third type
of VLP was derived from the commercial vaccine Gar-
dasil
®, and contained the serotypes HPV-16, -18, -6 and
-11. As expected, the mean absorbance value for the
levels of IgG antibodies detected in sera from the CIN 1
patients using either gVLP, VLP-L1, or cVLP were
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t h es a m ee x p e r i m e n t a la s s a yw ei n c l u d e dac o n t r o l
group selected from a previous study [22], consistent of
30 samples with reactivity of IgG antibodies for VLPs.
Taken into consideration the mean absorbance distribu-
tion of the sera reativity +3 SD of this control group to
gVLP, VLP-L1 and cVLP, the cut-off values for high reac-
tivity were of 1.1, 1.08 and 1.0 respectively (Figure 1B).
According with these cut-off values, we obtained two
distinct absorbance groups with cVLP that we called
high (group H) and low (group L) responders with
mean absorbance values of 1.68 ± 0.24 and 0.76 ± 0.14
respectively (Figure 1A). It is interesting to mention
that the average absorbance of the low responders in
group L was higher that that of any of those obtained
from the negative control sera. In the high responder
group using cVLP we had the serum samples of 11
patients (37%) while 19 patients in the low responder
group (63%). When we used VLP-L1 or gVLP we only
had 2 serum samples in the higher responder group
(7%). Our results thus suggest a more sensitive ELISA
assay when using cVLP as compared with those using
VLP-L1 or gVLP. We hypothesize that this significant
difference is due to presence of E6 and E7 antigenic
peptides fused to the L1 protein in the chimeric cVLP
particle. Of note, the patients that reported having more
sexual partners and pregnancies also presented higher
reactivity to the antigenic peptides E6 and E7 as well as
to cVLP (Figure 2, Table 1).
Detection of antibodies with specific neutralizing ability
for virus-like particles
Several studies have shown that infection with HPV
induces VLP-specific antibodies with neutralizing ability
that are maintained over long periods of time
[10,23-25]. To verify the specificity and neutralizing abil-
ity of these antibodies, hemagglutination inhibition
assays (HIA), based on the ability of the antibodies to
inhibit the interaction between virus-like particles with
cell receptors present in the membranes of erythrocytes
resulting in agglutination, have currently been used
[21,26,27]. In order to investigate whether antibodies in
the serum samples of patients with CIN 1 and infected
with HPV-16 have neutralizing activity, we employed an
HIA. Serial dilutions of serum samples from either
patients with CIN 1 and HPV infection or normal con-
trols were incubated with purified VLP-L1, cVLP, or
gVLP, and subsequently with mouse erythrocytes. We
found that between 11 and 12 serum samples out of 30
patients (approximately 40%) completely inhibited
gVLPs, VLP-L1 s, and cVLPs hemagglutination at 1:100
to 1:400 sera dilutions, while only between 4 to 6 serum
samples (approximately 20%) from normal donors inhib-
ited hemagglutination but only at 1:100 dilutions (Table 2).
We consider important to mention that less than 50%
of serum samples from patients with CIN 1 that had
high seropositivity to cVLPs had neutralizing ability for
any of the three types of VLPs used in this study
(Table 2).
Discussion
Persistent HPV-16 VLP serum antibodies are associated
with an increased risk of developing either carcinoma
in situ or invasive cervical cancer. Moreover, the pre-
sence of anti-E6 and anti-E7 antibodies is associated
with malignant progression of these cancers [28,29].
Optimal detection of antibodies specific for E6 and E7
antigens in conjunction with those specific for VLPs in
the incipient stages of the disease may be important to
evaluate the clinical outcome of viral infection and the
possible progression of this infection to cervical cancer.
In order to contribute to the early detection of these
antibodies, we utilized a novel plant-derived chimeric
virus-like particle (cVLP) composed of HPV-16 L1 and
a string of E6 and E7 antigenic peptides fused to the C-
terminus [21]. We designed an ELISA using cVLP for
the detection of specific antibodies in the sera of sub-
jects diagnosed with cervical intraepithelial lesion grade
1 (CIN 1) and HPV-16 DNA-positive genital tract tissue.
With respect to sera from CIN 1 patients, our results
demonstrated more sensitive detection of specific IgG
antibodies using cVLP versus those obtained with either
VLPs containing only the HPV-16 L1 protein (VLP-L1)
or with VLPs derived from the commercial vaccine Gar-
dasil (MSD, USA; gVLPs) (Figure 1). In addition, we
have obtained that sera of the patients used in this
study showed a similar reactivity to Cervarix (Glaxo SK,
UK) (0.72 of mean absorbance distribution) when this
vaccine was used as heterologous antigen. Interestingly,
our results using cVLP could be divided into two dis-
tinct groups: one group of serum samples had low titers
of antibodies (Group L, Figure 1), levels which were
similar to most of the results obtained from ELISAs
using VLP and gVLP and indicative of a high specificity
to the L1 protein; a second group which had serum
samples with very high antibody titers (Group H, Figure
1). The fact that these high antibody titers were detected
by ELISAs using epitopes from E6 and E7 proteins in
addition to L1 indicate that the specificity was for the
E6 and E7 antigenic peptides contained in cVLP (Group
H, Figures 1, 2 and Table 1).
The integration of HPV DNA increases oncogene
expression at various time points of viral pathogenesis
and malignant transformation [30]. Additionally, the
presence of antibodies specific for HPV-16 E6 and E7
proteins have often been associated with an increased
risk of subsequent carcinoma development [28,29].
Thus, the presence of specific antibodies to cVLPs
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Figure 1 Seroreactive response of patients with cervical intraepithelial neoplasia grade 1 (CIN 1) and HPV-16 infection to various
virus-like particles (VLPs). (A) IgG antibody responses to VLPs derived from: the commercial vaccine Gardasil
® (gVLP, circles) containing HPV-
16, -18, -6 and -11 serotypes; plant-based VLPs composed by HPV-16 L1 protein (VLP-L1, triangles); or chimeric particles containing the HPV-16 L1
sequence and sequences encoding E6 and E7 known antigenic peptides fused to the C-terminus (cVLP, squares), were determined in sera from
women with no evidence of HPV infection (normal, open symbols), and in sera from patients with CIN 1 and HPV-16 infection (HPV-16, filled
symbols). Results are divided into two specific groups of titers: a high-titer group (H) and a low-titer group (L). The mean absorbance distribution
of each group is represented by a solid line. Values of the mean absorbance distribution of the H and L groups are indicated by arrows. (B)
Shown are the mean absorbance distribution of the control positive group and the cut-off values for high seroreactivity at A 405 (indicated by
horizontal dashed lines and numbers) in response to gVLP (gray circles), VLP-L1 (gray triangles), and cVLP (gray squares). *Indicates difference
between groups is statistically significant. P-values were calculated using Wilcoxon signed-rank test and Student’s t-test.
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Page 4 of 11found in serum samples of the subjects with CIN 1, par-
t i c u l a r l yi nG r o u pH ,m a yi n d i c a t en o to n l yt h ep e r s i s -
tence of HPV-16 infection, but also the possible
integration of the viral genome in cervical epithelial
cells. Interestingly, cervical brush samples of patients
w i t hC I N1w e r en o to n l yp o s i t i v ef o rt h ep r e s e n c eo f
E6 and E7 HPV-16 genes as determined by PCR analy-
sis, but were also associated with patients who had a lar-
ger number of sexual partners (mean 3) and pregnancies
(mean 3.5) (Table 1), compared to control donors
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Figure 2 Seroreactive response of patients with CIN 1 and HPV-16 infection to HPV16 E6 and E7 antigenic peptides contained in
cVLPs. (A) The IgG antibody response in sera from donors without evidence of HPV infection (normal) and in sera from patients with CIN 1 and
HPV-16 infection (HPV-16), against antigenic peptides derived from HPV-16 proteins was determined by ELISA. The HPV-16 peptides were:
EIDGPAGQAEPDRAHYNI (E7 37-54), RAHYNIVTF (E7 49-57), PRKLPQLCTELQTTI (E6 16-30), and TLGIVCPI (E7 86-93). Additionally, the peptide
MQYEIINYM T6/GS (338-346), derived from the polymerase accessory protein, was used as a negative control. The mean absorbance value of
each group is represented by a solid line. (B) Shown are the mean absorbance distribution of the control positive group and the cut-off values
for high seroreactivity at A 405 (indicated by horizontal dashed lines and numbers) in response to the seroreactive peptides E7 37-54 (gray
circles), E7 49-57 (gray rhombus), E6 16-30 (gray squares), E7 86-93 (gray triangles). The seroreactivity to the irrelevant peptide T6/GS(338-346)
(tails) is also depicted. *Indicates difference between groups is statistically significant. P-values were calculated using Wilcoxon signed-rank test
and Student’s t-test.
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Page 5 of 11samples. In fact, large numbers of sex partners and
pregnancies have been reported as major risk factors
associated with persistent HPV infection and increased
risk of developing cervical dysplasia and cancer [31,32].
Because antibodies specific for HPV-16 E6 and E7 pro-
teins are associated with malignant progression of the
disease, and in fact are markers for HPV-associated
invasive cervical carcinoma, we hypothesize that the pre-
sence of high-titer antibodies specific for HPV-16 E6
and E7 epitopes in Group H patients with CIN 1 (Table 1)
may indicate a higher risk of cancer progression [33].
These conclusions have been further supported by
experiments involving synthetic peptides and proteins
translated in vitro or produced in bacteria or baculo-
virus/insect cell systems. These studies found that the
prevalence of anti-E6 and anti-E7 antibodies varies
from 16% to 60% in people with cervical uterine can-
cer, versus only 4% to 20% in normal donors [34-37].
In the present study, the results of ELISAs that con-
tained the peptides E7 37-54, E7 49-57, and E6 16-30
as individual antigens indicated that sera from 8 out of
the 11 CIN 1 patients had high titers of antibodies
specific for cVLP (Table 1). These results indicate that
these three epitopes were the ones bound by the
serum IgG antibodies from patients with CIN 1 conco-
mitant to a persistent HPV-16 infection.
Results from several studies have indicated that HPV
infection induces highly strain-specific neutralizing anti-
bodies based on the fact that recipients injected with
HPV-16, -18, -31, -52 and -58 VLPs develop neutralizing
antibodies specific for homologous HPVs efficiently and
with very limited cross-neutralization [11]. Furthermore,
patients with past and the persistent HPV can be identi-
fied by detection of anti-HPV strain-specific neutralizing
antibodies. In this study, we found that almost 40% of
the patients with CIN 1 and positive for DNA HPV-16
had serum antibodies specific for VLPs and with neutra-
lizing ability, which we determined with a hemagglutina-
tion inhibition assay. However, only a very few number
of serum samples from patients with CIN 1 (4 out of
30) and high titers of antibodies specific for cVLPs,
HPV-16 E6 and E7 peptides had VLP neutralizing activ-
ity. We hypothesize that these low levels of antibodies
with neutralizing ability in sera from these patients may
indicate a lack of sufficient protection against repeated
infection with either homologous or heterologous HPV
Table 1 Clinical data and seroreactive response to VLPs or HPV-16 E6 and E7 antigenic peptides in sera from CIN 1
patients
gVLP
(1.10)
VLP-L1
(1.08)
cVLP
(1.00)
E7(37-54)
(0.33)
E7(49-57)
(0.38)
E6(16-30)
(0.36)
Sera Neutralizing
dilution to VLPs
Number of sexual
partners [3.0]
Number of
Pregnancies [3.5]
1.933 0.364 0.475 0.364 - 5 4
1.790 0.433 0.473 0.392 - 2 3
1.760 0.337 0.493 0.434 - 2 5
1.670 0.264 0.466 0.214 - 1 2
1.628 1.751 1.633 0.293 0.342 0.301 1:100 2 5
1.791 0.311 0.241 0.253 1:100 2 4
1.299 1.423 1.969 0.386 0.425 0.444 - 3 3
1.686 0.371 0.446 0.500 - 5 4
1.790 0.299 0.277 0.297 1:100 4 2
1.113 0.324 0.386 0.269 1:200 2 3
1.383 0.537 0.571 0.409 - 3 4
Shown are the IgG serum antibody absorbances to VLPs or HPV-16 E6 and E7 antigenic peptides from CIN 1 subjects from Group H (Figure 1). The cut-off values
for a high seropositive response to each antigen are shown in parenthesis. Serum dilutions with neutralizing activity to VLPs are also indicated. Absence of
neutralizing activity is indicated by “(-)”. Mean numbers of sexual partners and pregnancies are shown in square brackets.
Table 2 Frequency of patients with CIN 1 and HPV-16
infection and normal donors who had serum titers of
antibodies with neutralizing activity to VLPs
SERA
ANTIGENS CIN 1 PATIENTS HPV-16+ NORMAL DONORS
6/30 (1:100)
gVLP 3/30 (1:200) 6/30 (1:100)
3/30 (1:400)
Total 12/30
5/30 (1:100)
VLP-L1 4/30 (1:200) 4/30 (1:100)
2/30 (1:400)
Total 11/30
5/30 (1:100)
cVLP 4/30 (1:200) 4/30 (1:100)
2/30 (1:400)
Total 11/30
Shown are results of hemagglutination inhibition assay (HIA) was performed
to measure titers of antibodies with neutralizing activity for specific VLP
particles in sera from women without evidence of HPV infection (normal) and
in sera from patients with CIN 1 and HPV-16 infection. Serum from each
person was assayed at various dilutions as described in the Materials and
Methods. Frequencies of patients and titers of antibodies with neutralizing
activity (in parentheses) for gVLPs, VLPs, and cVLPs are shown.
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associated with low levels of antibodies with neutralizing
ability may raise the risk of HPV E6/E7 oncogene-cell
DNA integration, leading to the initial step in cell
immortalization by HPV.
It would be interesting to repeat the present experi-
ments using a large number of serum samples from
patients infected with HPV strains other than HPV-16
and with sera from patients with CIN 1 and cervical
cancer. We hypothesize that the use of ELISAs using
the cVLPs described herein may be useful in monitoring
the pre-existing serostatus of women who have been
vaccinated with the recently introduced prophylactic
VLP-based vaccines. Furthermore, these ELISAs may be
useful in evaluating the vaccine response in women with
or without preexisting IgG antibodies specific for viral
particles, especially those antibodies specific for high-
risk viruses.
Lastly, we think that the ELISA described herein may
prove to be a useful tool in evaluating the risk of cancer
progression in women that have high titers of sera anti-
bodies specific for L1 plus E6 and E7 epitopes. Support-
ing this idea is the fact that longitudinal studies have
demonstrated that women with incident infection who
have seroconverted were 5 times more likely to have SIL
than women who had not seroconverted [24,25]. Addi-
tionally, the persistence of HPV-16 VLP serum antibo-
dies is also associated with increased risk of both
carcinoma in situ or invasive cervical cancer [16,17],
making this novel ELISA a potentially important clinical
tool.
Materials and methods
Study population and human samples
The study population was selected from patients attend-
ing the National Center for Clinics of Dysplasias (CEN-
ACLID), General Hospital of Mexico, and the
Department of Gynecology H.G.Z No. 2-A Troncoso,
IMSS, Mexico City, Mexico. Serum samples were col-
lected between February 2008 and July 2010 and
informed consent was obtained from all participants.
Human material was handled according to institutional
experimentation and safety guidelines. CENACLID pro-
vides gynecological services to women referred for col-
poscopy because of abnormal cytology and women who
do not have a history of cervical abnormalities but ask
for a routine examination. In the present study, women
in both groups were analyzed. All women underwent
cytological and histopathological analysis of colposcopy-
directed biopsies. Two experienced cytotechnologists
independently examined all Pap smears. Samples with
an inconsistent diagnosis were excluded from the study.
Cytology diagnoses were classified according to the
Bethesda System while the histopatological one, of the
Cervical Intraepithelial Neoplasia Grade I (CIN I), was
according to Richardt [39]. Samples with Cervical
Intraepithelial Neoplasia Grade II or III were excluded
from the study. All samples underwent molecular analy-
sis by PCR and hybrid capture. Women who were con-
sistently negative for both clinical and molecular tests
were considered negative controls. Only patients with
CIN 1 who had consistent positive results by PCR were
included in the study.
Blood samples, as well as cervical punch biopsy mate-
rial or cervical cells adequate for HPV DNA measure-
ment, were obtained both from patients with CIN 1
who were also positive for HPV-16 infection and from
negative controls. Cervical cells were collected by gently
swabbing the ectocervix with a cytobrush (Digene). Cer-
vical cells and biopsied tissues were placed immediately
in tubes containing sterile, contaminant-free PBS
(Roche) and processed the same day. Serum was isolated
from blood samples by centrifugation at 9000 g for
15 min. Serum samples were stored at -70°C until
tested. Investigators who performed molecular and
immunological assays were not aware of the clinical sta-
tus of samples. To avoid contamination, cases and con-
trols were tested in separate batches.
Detection of high- and low-risk HPV strains by hybrid
capture
The HPV Test Hybrid Capture II kit (Digene) was used
to detect high-risk HPV strains (16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59 and 68) or low-risk strains (6, 11,
42, 43 and 44). DNA (250-500 ng in 20 μl) was
extracted from cervical cells or tissues and placed in a
tube containing 30 μl specimen transport medium.
NaOH-based denaturation reagent (25 μl) was added to
each sample and the tubes were mixed vigorously and
incubated at 65°C for 45 min. Hybridization and hybrid
detection were performed according to the manufac-
turer’s instructions. Carrier DNA and plasmid DNA
containing the HPV-16 or HPV-11 genome were used
as negative and positive calibrators, respectively, and
were run in triplicate with each test. An assay was con-
sidered valid only when the results from the negative
and positive calibrators showed a coefficient of variation
≤15% and the positive-to-negative calibrator mean
values ratio was ≥2.0. The cut-off value for positivity
was calculated for each assay and was defined as the
mean relative light units (RLU) value of the positive cali-
brator. Samples that were positive for low-risk types
were excluded from this study.
HPV DNA detection by PCR
All reagents used in the isolation and amplification of
DNA were purchased from Gibco-BRL. Biopsies were
treated with proteinase K as described elsewhere [40].
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pitated with ethanol. HPV DNA was amplified using the
general primers MY09 (5’-CGTCCMARRGGAWACTG-
ATC-3’)a n dM Y 1 1( 5 ’-GCMCAGGGWCATAAYAA-
TGG-3’) [41], which amplified a conserved 450-bp
fragment from the L1 gene. Genomic DNA (100 ng)
was denatured by heating to 95°C for 30 s. Annealing of
primers was performed at 45°C for 30 s and extension
at 72°C for 60 s. The cycle was repeated 30 times. Speci-
fic amplification of HPV-16 was achieved by using the
primers Pr3 (5’-GTCAAAAGCCACTGTGTCCT-3’) and
Pr4 (5’-CATCCATTACATCCCGTAC-3’), which ampli-
fied a 499-bp fragment covering the HPV-16 E7 gene
plus fragments of the E6 and E1 genes. Amplification of
HPV-18 was performed using the primers Pr1 (5’-
CCGAGCACGACAGGAACGACT-3’)a n dP r 2( 5 ’-
TCGTTTTCTTCCTCTGAGTCGCTT-3’), which ampli-
fied a 172-bp fragment including parts of the HPV-18 E6
and E7 genes, as described previously [42]. To ensure
DNA integrity, the b-globin gene was amplified using the
primers PC03 and PC04 as described previously [43]. As
ap o s i t i v ec o n t r o l ,P C Ro fD N Af r o mS i H a( ac e r v i c a l
cancer-derived cell line containing one to two HPV-16
copies per cell) or HeLa (a cervical cancer-derived cell
line positive for HPV-18) cells was performed concur-
rently with each reaction. Additionally, negative controls
to assess the presence of contaminants were carried out
using purified water (Gibco-BRL) and PBS instead of
template DNA. Patients whose DNA sample could not be
amplified were excluded from the study.
VLPs and antigenic peptides
We previously reported the expression in tomato plants
of VLPs containing the HPV-16 L1 sequence (VLP-L1)
and a chimeric particle (cVLP) containing the HPV-16
L1 sequence and a string of sequences encoding T cell
epitopes fused to the C-terminus, which codes for the
amino acids 16-30 from E6 and 37-54, 49-57, and 86-93
from E7 [21]. VLPs used in this work were either pro-
cessed from these transgenic plants or from the com-
mercial HPV vaccine Gardasil
® (gVLP). VLPs derived
from transgenic plants were purified by using immu-
noaffinity columns, as described previously [21]. Briefly,
tomatoes were lysed with extraction buffer (PBS pH 7.4
with 1 mM PMSF) on ice. The homogenates were clari-
fied by centrifugation at 10,000 rpm for 30 min at 4°C
and filtered through Whatman paper No. 1 and then
through a Millipore 0.8-μm filter. The supernatant was
then applied to an affinity column, which was prepared
by coupling sera from women vaccinated with three
doses of the commercial HPV vaccine Gardasil
® vaccine
to 4B CNBr-Sepharose (Sigma). The columns were
washed with 50 vol of washing buffer (50 mM Tris-HCl,
5 mM EDTA, 150 mM NaCl, 0.1% NP-40, pH 7.4),
followed by 50 vols of the same buffer without NP-40.
VLPs were eluted with 100 mM HCl-glycine, pH 4.0.
The VLP-containing fractions were neutralized with 100
mM Tris-HCl (pH 9.0) and dialyzed against PBS over-
night. The VLPs obtained from transgenic plants was
verified by transmission electron microscope, as pre-
viously reported [21].
The quantity of plant-purified VLP-L1/cVLP was mea-
sured by ELISA. For this purpose, ELISA plates (Corning)
were coated with 100 μl of chromatography-purified
VLP-L1 and cVLPs. Gardasil
® vaccine dilutions contain-
ing from 10 to 160 ng of HPV-16 VLPs/100 μLw e r e
used as standard. All samples were tested in triplicate.
Plates were incubated for 16 h at 4°C, washed twice in
TBS-0.1% Tween-20, blocked with 2% w/v bovine serum
albumin (BSA) in TBS-0.1% Tween-20, and incubated for
2 h at 37°C. Plates were washed four times, and incubated
with sera from women vaccinated with three doses of
commercial vaccine at 1:500 in blocking buffer. After 2 h
at 37°C, plates were washed 6 times and incubated with
1:5000 rabbit-anti-human IgG (Zymed, USA). Plates were
incubated for an additional 2 h at 37°C. After eight
washes, alkaline phosphatase substrate (Sigma) was
diluted in a 10% diethanolamine solution (pH 9.8) and
added to the plates. The absorbance at 405 nm was mea-
s u r e db yE L I S Ap l a t er e a d e r .T h ec o n c e n t r a t i o no fV L P s
was calculated by average of three repeats.
The following antigenic peptides were synthesized
by Invitrogen: From HPV-16 E6 protein, 16-30
PRKLPQLCTELQTTI [44,45]; from HPV-16 E7 protein,
37-54 EIDGPAGQAEPDRAHYNI [46], 49-57 RAHY-
NIVTF [47], and 86-93 TLGIVCPI [44,45]. Peptides
were dissolved in PBS and stored at -70°C before use.
The peptide 338-346 MQYEIINYM derived from T6/GS
polymerase accessory protein was used as irrelevant
control [48].
ELISA for detecting anti-VLP and anti-peptide antibodies
The specific titers of serum antibodies specific for VLPs
and peptides from in subjects with LSIL and negative
controls were determined by ELISA. ELISAs were per-
formed with gVLP or VLP-L1 and cVLP obtained from
transgenic plants, as well as the antigenic peptide encod-
ing sequences contained in the C-terminus of the
cVLPs, were used as antigens in ELISA assays. For this
purpose, each type of VLP was diluted in PBS at 1 μg/
ml, and the peptides were diluted at 5 μg/ml in sodium
carbonate/bicarbonate buffer (0.1 M sodium carbonate,
0.1 M sodium bicarbonate, pH 9.6). ELISA plates were
coated with 100 μlo fV L P sa n di n c u b a t e df o r1 6ha t
4°C. Plates were then washed four times with TBS con-
taining 0.1% Tween 20 (TBS/Tween 20). Non-specific
binding sites were blocked with 200 μl 2% BSA in TBS/
Tween-20 for 2 h at 37°C. After washing, 100-μls e r u m
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and the plates were incubated at 37°C for an additional
2 h. After washing, alkaline phosphatase-conjugated rab-
bit-anti human IgG (Dako) was diluted in blocking buf-
fer at 1:500 and 100 μl was added to each well. The
plates were then incubated for 2 h at 37°C. After wash-
ing, alkaline phosphatase substrate Sigma 104 was
diluted in a 10% diethanolamine solution (pH 9.8) and
added to the plates. The absorbance at 405 nm was
measured by an ELISA plate reader. The assay was con-
sidered valid only when the coefficient of variation of
the triplicates was ≤10%. Additionally, all samples were
tested in two wells not coated with VLPs or peptides to
define non-specific reactivity. The final ELISA value was
calculated by subtracting the non-specific reactivity
mean absorbance from the triplicate mean absorbance.
To control for inter-assay variation, positive IgG con-
trols selected from a previous study [22] were included
in each plate and tested as described. Plates with an
inter-assay coefficient of variation >10% were not con-
sidered valid. The cut-off value for high seroreactivity
was determined on the basis of the absorbance distribu-
tion of the 30 positive control group samples to VLPs
and peptides and was defined as the mean absorbance
+3 SD after exclusion of outliers.
Hemagglutination inhibition assay
Hemagglutination inhibition assays were performed
according to Roden et al. [26]. Mouse blood was col-
lected in a heparinized tube and erythrocytes were sepa-
rated by centrifugation at 1,000 rpm for 5 min at 4°C,
washed twice with PBS and suspended in dilution buffer
(1% BSA in PBS) at a concentration of 1% (v/v). VLP-L1 s,
cVLPs, or gVLPs (100 ng) were then incubated with var-
ious dilutions of serum samples (from 1:100 to 1:1600) at
room temperature for 2 h, after which the samples were
diluted with an equal volume of the 1% RBC suspension.
Aliquots of the mixtures (100 μl) were transferred to a
round-bottomed, 96-well plate and incubated for 3 h at
4°C. Spots indicating VLP neutralizing activity were photo-
graphed and analyzed.
Statistical analysis
All numerical data are expressed as an average of values
obtained ± standard deviation (SD), and all samples were
tested in triplicate. The Wilcoxon signed-rank test and Stu-
dent’s t-test were used to compare the mean signal strength
(absorbance) of the various groups. All tests were two-
tailed and P < .05 was considered statistically significant.
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